The number of institutions offering clinical exome or genome tests to healthy individuals keeps increasing, but the practice remains controversial among medical experts.
The pediatric health system will use RPRD's pharmacogenomics testing platform in its cancer and blood disorder clinic and its neurology/psychology practice.
The company, which raised the money from Silicon Valley Bank as well as existing shareholders, said it will use the proceeds to expand its business.
The deal brings together two firms to create new "drug knowledge" to inject pharmacogenomics into clinical workflows.
Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The PGx firm can offer its RightMed test in 49 states and plans to seek certification in New York this year.
Healthcare providers who use CGM EHR solutions can receive ActX real-time drug dosing, adverse reaction alerts, and patient genomic profiles.
The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
Inova plans to offer broad and condition-specific PGx gene panels in its specialty clinics and is negotiating with payors for reimbursement.
Admera's 50-gene PGxOne Plus assay can help predict how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.